Is Cochlear a buy?

The hearing implant manufacturer's share price has been somewhat rocky, but the long-term future looks positive.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear (ASX: COH) is the global leader in the provision of hearing implant devices, and sales growth prospects look solid. It has a large global presence, with direct operations in over 20 countries and products sold in over 100 countries.

Fluctuating foreign exchange rates have impacted the business, and the Australian dollar's recent fall has seen the share price recover from a profit downgrade at the end of June.

Cochlear's main opportunity for sustainable growth comes through the large unmet clinical markets for its products across the world. Emerging markets, particularly two of the world's most populous countries, China and India, remain a focus.

The profit premium here is lower than in its main market, the United States, but the potential for sales growth is greater. Furthermore, the company's competitive advantage — having the best technology going — has allowed it to dominate the global market in recent years.

To maintain or even increase this advantage, the business continues to invest heavily in research and development. One such product developed as a result of this investment is its latest implant device, the Nucleus N6. Recently launched after having been in development for over six years, the success of this device could be crucial to the company's 2014 performance.

The N6 is said to be the start of a new range of products to be launched in the coming year, based on the latest sound processing technologies.

The company relies on investment in new technologies and innovations to translate into greater profits and sales. At today's prices, a P/E ratio over 26 is demanding, however a dividend yield in the region of 3.8% provides some reliable income.

Foolish takeaway

The fundamentals for the business remain strong and investors will hope new technology means 2014 brings strong all-round results with it. Those bearish on the Australian dollar will also find the business of particular interest.

Looking for a few more solid investment ideas? The Australian Financial Review says "good quality Australian shares that have a long history of paying dividends are a real alternative to a term deposit." Get "3 Stocks for the Great Dividend Boom" in our special FREE report. Click here now to find out the names, stock symbols, and full research for our three favourite income ideas, all completely free!

More reading


Motley Fool contributor Tom Richardson owns shares in Cochlear.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »